跳转至内容
Merck
CN
所有图片(1)

主要文件

E0085000

Eicosapentaenoic acid ethyl ester

European Pharmacopoeia (EP) Reference Standard

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C22H34O2
CAS号:
分子量:
330.50
MDL编号:
UNSPSC代码:
41116107
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

eicosapentaenoic acid

制造商/商品名称

EDQM

应用

pharmaceutical (small molecule)

包装形式

neat

运输

wet ice

储存温度

−20°C

SMILES字符串

O(CC)C(=O)\C=C\C=C\C=C\C=C\C=C\CCCCCCCCC

InChI

1S/C22H34O2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24-4-2/h12-21H,3-11H2,1-2H3/b13-12+,15-14+,17-16+,19-18+,21-20+

InChI key

DTEMJWLYSQBXEL-MBFZXKRTSA-N

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Eicosapentaenoic acid ethyl ester EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Eun Young Park et al.
Journal of agricultural and food chemistry, 53(21), 8334-8341 (2005-10-13)
The effects of the addition of amino acids and peptides on the oxidation of eicosapentaenoic acid ethyl ester (EPE) encapsulated by maltodextrin (MD) were investigated. The encapsulated lipid was prepared in two steps, that is, by mixing of EPE with
Abbie L Cawood et al.
Atherosclerosis, 212(1), 252-259 (2010-06-15)
To examine n-3 polyunsaturated fatty acid (PUFA) incorporation into atherosclerotic plaques and the association with plaque inflammation and stability. Patients awaiting carotid endarterectomy (n=121) were randomised to consume control capsules or n-3 PUFA ethyl ester capsules until surgery (median 21
Christie M Ballantyne et al.
The American journal of cardiology, 110(7), 984-992 (2012-07-24)
AMR101 is an ω-3 fatty acid agent containing ≥96% pure icosapent-ethyl, the ethyl ester of eicosapentaenoic acid. The efficacy and safety of AMR101 were evaluated in this phase 3, multicenter, placebo-controlled, randomized, double-blinded, 12-week clinical trial (ANCHOR) in high-risk statin-treated
Agnes K Ayton et al.
Prostaglandins, leukotrienes, and essential fatty acids, 71(4), 205-209 (2004-08-11)
Anorexia nervosa (AN) carries the highest risk of morbidity and mortality amongst psychiatric disorders. The efficacy of current treatment approaches is limited. Despite the fat-phobic nature of the disease, poly-unsaturated fatty acids (PUFAs) have not received much research attention. Patients
Terry A Jacobson
Expert review of cardiovascular therapy, 10(6), 687-695 (2012-08-17)
ω-3 fatty acids reduce triglyceride (TG) levels, but corresponding increases in low-density lipoprotein cholesterol (LDL-C) levels may compromise achievement of lipid goals in patients with elevated cardiovascular risk. AMR101 is an investigational agent containing ≥96% of pure icosapent ethyl (the

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门